title: [Analysis of the prevalence of CCR5 coreceptor antagonist resistance mutations among HIV-1 variants in Russia].
abstract: The authors studied the prevalence of mutations associated with resistance to the CCRS coreceptor antagonists maraviroc and vicriviroc in Russia. Most (93.6%) patients infected with HIV-1 genetic subtype A (IDU-A), predominant in the CIS countries, were found to have maraviroc resistance mutations. These mutations appear to reflect the natural genome polymorphism characteristic of the variant IDU-A. Maraviroc resistance mutations were of limited occurrence (2.8%) among the samples of virus subtype B in Russia. There were no vicriviroc resistance mutations in both the HIV-1 genetic variant IDU-A and the samples of virus subtype B. There is a need for further clinical studies evaluating the real impact of these mutations on the efficacy of maraviroc in patients infected with the HIV-1 genetic variant IDU-A.
authors.forename: A V
authors.initials: AV
authors.lastname: Vasil'ev
authors.forename: E V
authors.initials: EV
authors.lastname: Kazennova
authors.forename: M R
authors.initials: MR
authors.lastname: Bobkova
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000008:administration & dosage* / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000187:drug effects*; D014644:Genetic Variation; D016679:Genome, Viral / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D000077592:Maraviroc; D009154:Mutation / Q000187:drug effects; D010802:Phylogeny; D010879:Piperazines / Q000008:administration & dosage* / Q000627:therapeutic use; D015995:Prevalence; D011743:Pyrimidines / Q000008:administration & dosage* / Q000627:therapeutic use; D019713:Receptors, CCR5 / Q000235:genetics / Q000378:metabolism; D012426:Russia; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D010879:Piperazines; D011743:Pyrimidines; D019713:Receptors, CCR5; D014230:Triazoles; D000077592:Maraviroc; C486781:vicriviroc